Latest News for: granulosa cell tumor

Edit

Pine survivor’s story promotes early checks for ovarian cancer

Pittsburgh Tribune Review 09 Oct 2024
“And eventually, the workup showed that there was a big tumor, about 14 centimeters.”. The medical term is a Stage 1a juvenile granulosa cell tumor, indicating that it was detected and treated before a potential spread of the cancer.
Edit

Young Pine-Richland survivor joins fight against ovarian cancer

Pittsburgh Tribune Review 19 Sep 2024
Diagnosed with Stage 1a juvenile granulosa cell tumor ovarian cancer shortly after her fifth birthday, Desolina today is an advocate for cancer research, awareness and fundraising.
Edit

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and ...

Enid News & Eagle 27 Feb 2024
... industry and academic collaborator studies evaluating nirogacestat as part of B-cell maturation antigen (BCMA) combination therapy regimens across treatment lines in patients with multiple myeloma.
Edit

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at ...

The Eagle-Tribune 08 Jan 2024
... evaluate nirogacestat in patients with multiple myeloma as part of several B-cell maturation antigen (BCMA) combination therapy regimens across treatment lines in collaboration with industry leaders.
Edit

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and ...

The Eagle-Tribune 28 Nov 2023
SpringWorks is also evaluating nirogacestat as a potential treatment for patients with ovarian granulosa cell tumors and for patients with multiple myeloma as part of several B-cell maturation agent ...
Edit

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Enid News & Eagle 02 Nov 2023
... of life that were previously reported with nirogacestat.The ongoing Phase 2 trial evaluating nirogacestat as a monotherapy in patients with recurrent ovarian granulosa cell tumors is fully enrolled.
Edit

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of ...

The Eagle-Tribune 01 Nov 2023
SpringWorks is also evaluating nirogacestat as a potential treatment for patients with ovarian granulosa cell tumors and for patients with multiple myeloma as part of several B-cell maturation agent ...
Edit

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business ...

Eagle-Tribune 02 Aug 2023
– Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – ... nirogacestat as a monotherapy in patients with recurrent ovarian granulosa cell tumors.
Edit

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

Eagle-Tribune 05 Jun 2023
Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which is believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.
Edit

Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

Victoria Advocate 01 Jun 2023
... achieved full enrollment in its Phase 2 trial evaluating nirogacestat, an investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors (OvGCT).
Edit

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in ...

Enid News & Eagle 30 May 2023
About Ovarian Granulosa Cell Tumors. Ovarian granulosa cell tumors (OvGCT) are a rare ovarian cancer subtype that are usually slow-growing tumors ... Mutation of FOXL2 in granulosa-cell tumors of the ovary ... Granulosa cell tumor of the ovary.
Edit

Vaginal Prolapse (Buwá in Tagalog) in Pets: Causes, Diagnosis, and Treatment

Manila Standard 27 May 2023
Simply put, hyperplasia indicates that there is more tissue than there should be due to the presence of more cells ... (Photo from the article, “Vaginal prolapse related to ovarian granulosa cell tumor in an Anatolian Shepherd.”).
Edit

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination ...

Enid News & Eagle 11 May 2023
Nirogacestat is an oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors and in Phase 2 clinical development for ovarian granulosa cell tumors.
Edit

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Eagle-Tribune 03 May 2023
... an NDA to the FDA for mirdametinib as a treatment for NF1-PN in the first half of 2024.Patients continue to be enrolled in a Phase 2 trial evaluating nirogacestat in ovarian granulosa cell tumors.
Edit

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi ...

Eagle-Tribune 08 Mar 2023
Nirogacestat is an oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors and in Phase 2 clinical development for ovarian granulosa cell tumors.

Most Viewed

×